Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 8/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PYGB | P11216 | 2/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30034655 | 0.84 | SLC5A2 (0.47) | SLC5A1SLC5A2 | |
| SCHEMBL29616303 | 0.74 | SLC5A2 (0.49) | SLC5A1SLC5A2 | |
| SCHEMBL31498348 | 0.73 | SLC5A2 (0.48) | SLC5A1SLC5A2 | |
| SCHEMBL29555015 | 0.69 | GBA1 (0.36) | PYGB | |
| SCHEMBL3868207 | 0.68 | GBA1 (0.37) | PYGB | |
| SCHEMBL27840040 | 0.68 | SLC5A2 (0.45) | SLC5A1SLC5A2 | |
| SCHEMBL27497543 | 0.68 | SLC5A2 (0.45) | SLC5A1SLC5A2 | |
| SCHEMBL9081470 | 0.67 | LMNA (0.61) | PTGS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31207232 | 0.66 | GBA1 (0.36) | PYGB | |
| SCHEMBL29454922 | 0.66 | GAA (0.38) | PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-20250353870-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2025-11-20 | — | — | US | disclosed |
| US-12312378-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2025-05-27 | — | — | US | disclosed |
| US-20240051982-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-02-15 | — | — | US | disclosed |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353870-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | MAOB 845/4885SLC5A1 10/4885SLC5A2 19/4885 |
| US-20240051982-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | OGT, UGGT1, FUT6 | MAOB 814/4885SLC5A1 22/4885SLC5A2 30/4885 |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, GLA | MAOB 1096/4885SLC5A1 15/4885SLC5A2 28/4885 |
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | SOST, FUT6, SLC5A1 | MAOB 1541/4885SLC5A1 3/4885SLC5A2 7/4885 |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | MAOB 845/4885SLC5A1 10/4885SLC5A2 19/4885 |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | OGT, UGGT1, GLA | MAOB 845/4885SLC5A1 10/4885SLC5A2 19/4885 |
| US-12312378-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, FUT6 | MAOB 814/4885SLC5A1 22/4885SLC5A2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.